Metabolic · In Clinical Trials
Survodutide
No lawful US pathway
01 · Overview
Survodutide is a dual agonist of the glucagon and glucagon-like peptide-1 (GLP-1) receptors, given as a once-weekly subcutaneous peptide injection. The compound is designed to combine GLP-1-mediated glucose control and appetite suppression with glucagon-driven increases in energy expenditure and effects on liver fat.
It is being investigated for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH).
02 · Research summary & key findings
In a 46-week phase 2 obesity trial, survodutide reduced body weight dose-dependently by up to about 15 percent, with gastrointestinal adverse events in 75 percent of recipients (PMID 38330987). In a phase 2 trial in biopsy-confirmed MASH with fibrosis, 43 to 62 percent of survodutide groups had MASH improvement without worsening fibrosis versus 14 percent with placebo, and liver fat fell by at least 30 percent in most treated participants (PMID 38847460). In the phase 3 SYNCHRONIZE-1 trial, weight change at 76 weeks was -12.2 to -13.0 percent versus -5.4 percent with placebo (PMID 42253238).
03 · Regulatory status
Survodutide is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
No lawful pathway today
Survodutide is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 13 FDA-approved compounds in Metabolic
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for metabolic health and weight?
Survodutide is still in clinical trials, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on metabolic health and weight, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection
References
- [1]Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial Lancet Diabetes Endocrinol, 2024. PMID 38330987
- [2]A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis N Engl J Med, 2024. PMID 38847460
- [3]Survodutide Once Weekly for the Treatment of Adults with Obesity N Engl J Med, 2026. PMID 42253238
Primary literature
- PubMed: "Survodutide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Survodutide"
Registered interventional and observational studies, including status and phase.
- PubChem: "Survodutide"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Metabolic
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.